Clinical Trial Update: Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View source ↗

Summary

A completed clinical trial assessing dabigatran etexilate 150 mg once daily for prevention of thromboembolism after hip or knee replacement in patients with mod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthroplasty, Replacement, Thromboembolism | Status: COMPLETED | Results posted: 2015-09-25